Summer Sale

50% off Premium Yearly

00days
00hrs
00mins
00secs
BLX 0.57ELF.TO 0.09RY.TO 3.05PEY.TO 0.26CP.TO -0.12BRK.B -0.57MSFT -5.93META 6.73
Daily Stock Opinions and Ratings
Stockchase Opinions

Alexander Lane, B Comm, CAngiotech PharmaceuticalsANP.TODON'T BUYFeb 06, 2007

Have been a lot of concerns on their stent products. As a result of this, they acquired a company that would give them revenue and earnings in the event the stents were pulled. Still a lot of risks.
Alexander Lane, B Comm, CAlexander Lane, B Comm, C
No
Unlock Rating
$8.58

Stock price when the opinion was issued

biotechnologypharmaceutical
It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.
Get Signals Create your Watchlist

You might be interested:

DON'T BUY

Angiotech Pharmaceuticals(ANP.TO)

Feb 01, 2010
What hurts them was they levered up for an acquisition using debt at the wrong time and have never been able to get out from under that cloud of debt and he doesn't think they will.
Photo of John ZechnerJohn Zechner
No
Unlock Rating
$1.21

Stock price when the opinion was issued

biotechnologypharmaceutical
BUY ON WEAKNESS

Angiotech Pharmaceuticals(ANP.TO)

Jun 22, 2009
(Market Call Minute.) A lot of biotech stocks have done well. Would buy on a pullback.
Photo of Robert McWhirterRobert McWhirterUnlock Rating
$1.90

Stock price when the opinion was issued

biotechnologypharmaceutical
DON'T BUY

Angiotech Pharmaceuticals(ANP.TO)

Jun 12, 2009
Had 2 approvals, May 27 and June 8. This is on his Watch list but was far more interesting before May 27 so it now holds no interest for him. Might be okay for momentum players.
Photo of Benj GallanderBenj Gallander
No
Unlock Rating
$2.15

Stock price when the opinion was issued

biotechnologypharmaceutical
COMMENT

Angiotech Pharmaceuticals(ANP.TO)

Dec 11, 2007
The stock has been hurt, but it is more of an issue because of stents. Sales projections are falling off. At this stage, you are probably facing tax loss selling for the rest of the month and then get a January bounce if the company has a decent outlook going forward. Competition has increased in this area.
Photo of Robert FloydRobert Floyd
No
Unlock Rating
$3.66

Stock price when the opinion was issued

biotechnologypharmaceutical
HOLD

Angiotech Pharmaceuticals(ANP.TO)

Jul 05, 2007
Have had serious problems with their stents. The whole area is having issues. Excellent management. They have big pipeline and the technology is still excellent.
Photo of Chyanne FickesChyanne FickesUnlock Rating
$7.31

Stock price when the opinion was issued

biotechnologypharmaceutical
SELL

Angiotech Pharmaceuticals(ANP.TO)

Jun 01, 2007
The whole market is going up, and this one is going down. Let someone else own it.
Photo of Kenneth P. Norquay, CMTKenneth P. Norquay, CMT
No
Unlock Rating
$7.22

Stock price when the opinion was issued

biotechnologypharmaceutical
SELL

Angiotech Pharmaceuticals(ANP.TO)

May 01, 2007
A one trick pony with its coated stent. There is lots of controversy on drug coated stents.
Photo of Norman LevineNorman Levine
No
Unlock Rating
$6.29

Stock price when the opinion was issued

biotechnologypharmaceutical
DON'T BUY

Angiotech Pharmaceuticals(ANP.TO)

Apr 19, 2007
They're very focused on one part of the business, which is stents. There is a lot of competition in this sector. Revenue projections have been dropping.
Photo of Robert FloydRobert FloydUnlock Rating
$6.85

Stock price when the opinion was issued

biotechnologypharmaceutical
COMMENT

Angiotech Pharmaceuticals(ANP.TO)

Apr 17, 2007
Makes drug alluding stents. Its penetration rate in the US was 75% but has dropped to 65%. Will be launching in Japan in the fall. Have a lot of debt on the balance sheet and are in the process of selling assets.
Photo of Chyanne FickesChyanne FickesUnlock Rating
$6.99

Stock price when the opinion was issued

biotechnologypharmaceutical
BUY

Angiotech Pharmaceuticals(ANP.TO)

Apr 02, 2007
The worst news is already in the stock. At these levels, it's a Buy. Have product pipeline starting to develop. Looking at drug eluding stents in the Japanese market.
Photo of John ZechnerJohn Zechner
Owned
Unlock Rating
$6.17

Stock price when the opinion was issued

biotechnologypharmaceutical
DON'T BUY

Angiotech Pharmaceuticals(ANP.TO)

Mar 28, 2007
A “ one trick pony”. There are now lots of questions to the effectiveness of drug-coated stents.
Photo of Norman LevineNorman Levine
No
Unlock Rating
$6.38

Stock price when the opinion was issued

biotechnologypharmaceutical
DON'T BUY

Angiotech Pharmaceuticals(ANP.TO)

Mar 12, 2007
Not time to buy this one yet. They have the stent problem and the adoption problem. Lowering their earnings forecasts. Potential recovery, but wait for the recovery.
Photo of Peter HodsonPeter Hodson
No
Unlock Rating
$7.20

Stock price when the opinion was issued

biotechnologypharmaceutical
DON'T BUY

Angiotech Pharmaceuticals(ANP.TO)

Mar 12, 2007
Had a long-term problem with stents. Made a series of acquisitions which all look very interesting. Not sure what the effect of this will be. A raving buy at this price, but does not like buying a stock on the way down.
Photo of Chyanne FickesChyanne Fickes
Owned
Unlock Rating
$7.20

Stock price when the opinion was issued

biotechnologypharmaceutical
DON'T BUY

Angiotech Pharmaceuticals(ANP.TO)

Mar 09, 2007
If it breaks $7.35, it is going to go lower. His model price is hugely coming down. In September it was $16 and now it is $10.73, which is a positive differential, but earnings are dropping.
Photo of Brian Acker, CABrian Acker, CA
No
Unlock Rating
$7.37

Stock price when the opinion was issued

biotechnologypharmaceutical
DON'T BUY

Angiotech Pharmaceuticals(ANP.TO)

Feb 13, 2007
Guidance for this year was quite poor. Their stent business is not going to be as robust. Company needs to diversify their asset base and have been slow to do that.
Photo of Robert FloydRobert FloydUnlock Rating
$7.83

Stock price when the opinion was issued

biotechnologypharmaceutical

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

AVGO -17.23$376.71
CCO.TO 1.26$151.04
TOU.TO -0.47$60.79
BTE.TO -0.22$5.91
ADM -1.25$78.02
The ultimate 360° Tracker Your financial life in one place, automaticallywealthica-video

Today's Top Picks

BLX 0.57$59.24
ELF.TO 0.09$16.98
RY.TO 3.05$281.51
PEY.TO 0.26$24.91
CP.TO -0.12$124.8

Popular Articles

Latest Sell Signals

OTEX.TO 0.14$30.96
BSX 0.16$46.92
GIL.TO -16.24$70.39
SHOP.TO 1.22$158.49
WCN.TO 3.21$219.59

Most Recent Experts

The Panic-Proof Portfolio (Stockchase Research)

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Keith Richards

Keith Richards

ValueTrend Wealth Management

Joe Terranova

Joe Terranova

Virtus Investment Partners

Stephen Weiss, Founder, Short Hills Capital Partners

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Rob Sechan, Managing Partner, New Edge Capital

Rob Sechan, Managing Partner, New Edge Capital

New Edge Capital

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica
The ultimate 360° Tracker Your financial life in one place, automaticallywealthica-video